Glecaprevir and Acarbose: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Acarbose
Glecaprevir
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You're taking acarbose to help control your blood sugar, and glecaprevir to clear a hepatitis C infection. Here's the key point: as the hepatitis C treatment heals your liver, your body may start handling blood sugar differently. Because your diabetes medicine is still working the same, your blood sugar can drop too low. Low blood sugar can cause shaking, sweating, confusion, or feeling faint.
The good news is this is very manageable. Your care team can watch your numbers more closely and adjust your diabetes medicine if needed. Keep taking both medicines as prescribed, check your blood sugar as advised, and let your doctor or pharmacist know if you feel any low-sugar symptoms.
Effect: Altered glycemic control with risk of serious symptomatic hypoglycemia when acarbose is used during glecaprevir (glecaprevir/pibrentasvir) therapy.
Mechanism: Not a classic PK enzyme/transporter interaction. Clearance of HCV infection with direct-acting antivirals can improve hepatic function and insulin sensitivity, enhancing the glucose-lowering effect of existing antidiabetic therapy.
- Direction: Increased antidiabetic effect (hypoglycemia risk).
- Onset: Unspecified; may evolve over the treatment course.
- Evidence: Probable (postmarketing case reports, epidemiologic studies).
- Management: Monitor blood glucose more frequently; individualize acarbose dose or consider discontinuation as clinically indicated.
What happens
Altered glycemic control resulting in severe symptomatic hypoglycemia
Interaction Deep Dive
When HCV infection is cleared using direct-acting antivirals, resulting shifts in liver function can affect how safely and effectively other medications are used at the same time. Both postmarketing case reports and published epidemiological research have described disturbances in blood glucose regulation leading to serious symptomatic hypoglycemia among diabetic patients. During concurrent administration of glecaprevir/pibrentasvir, blood glucose should be checked more often, and clinicians should weigh whether to modify the dose of antidiabetic agents or stop them altogether1.
Why it happens (mechanism)
Changes in hepatic function due to clearance of HCV infection with direct-acting antivirals
How to manage this interaction
This interaction is very manageable with the right follow-up.
- Keep taking both medicines as prescribed unless your care team tells you otherwise.
- Check your blood sugar more often during and after your hepatitis C treatment, as your team advises.
- Your acarbose dose may need to be adjusted and individualized by your care team, and in some cases they may pause or change it.
- Learn the signs of low blood sugar (shakiness, sweating, dizziness, confusion) and know how to treat it quickly.
Talk with your pharmacist or prescriber about a monitoring plan and report any low-sugar symptoms right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) Changes in blood glucose control leading to serious symptomatic hypoglycemia have been documented in diabetic patients through postmarketing case reports and published epidemiological studies 1.
Common questions
Can I take Glecaprevir and Acarbose together?
Clearing hepatitis C with glecaprevir can improve liver function and make acarbose lower your blood sugar more than before, risking hypoglycemia. Keep taking both as prescribed, monitor your blood sugar more closely, and let your care team adjust your diabetes medicine as needed. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Glecaprevir and Acarbose interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Glecaprevir and Acarbose interaction managed?
This interaction is very manageable with the right follow-up. Keep taking both medicines as prescribed unless your care team tells you otherwise. Check your blood sugar more often during and after your hepatitis C treatment, as your team advises. Your acarbose dose may need to be adjusted and individualized by your care team, and in some cases they may pause or change it. Learn the signs of low bl… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Glecaprevir or Acarbose need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (1)
- Product Information: MAVYRET(R) oral tablets, oral pellets, glecaprevir pibrentasvir oral tablets, oral pellets. AbbVie Inc (per FDA), North Chicago, IL, 2023. DailyMed
Keep reading about Acarbose
Keep reading about Glecaprevir
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist